Onyx Biotec logo

Onyx Biotec financials and balance sheet

NSE: ONYXPharmaceuticals & Biotechnology

Last close ₹37.00₹0.00 (0.00%)

Share price at the NSE close on 23 Oct 2026. Previous close ₹37.00.

52-week range of traded prices to 23 Oct 2026
₹24.20Low, 22 May 2026₹49.65High, 5 Aug 2026
Market cap
₹67 Cr
P/E
Lossover the last 12 months
P/B
1.2
Dividend yield
Nonein the last 12 months
ROE
−0.4%
Debt to equity
0.27
Volume, NSE
4,000100.0% delivered

2 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Onyx Biotec annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
Peak revenue ₹69 Cr, year to Mar 2026A loss in the year to Mar 2026, −₹0.21 Cr

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue69
  2. Materials and goods−52
  3. Employee costs−8.6
  4. Other expenses−5.8
  5. Operating profit3.4
  6. Depreciation−3.1
  7. Other income+0.4
  8. Finance costs−1.2
  9. Profit before tax−0.4
  10. Tax+0.2
  11. Net profit−0.2

What the company owns

  • Plant, investments and other assets₹50 Cr
  • Receivables₹27 Cr
  • Inventory₹14 Cr
  • Cash and bank₹4 Cr

What pays for it: net worth and liabilities

  • Net worth₹55 Cr
  • Owed to suppliers₹18 Cr
  • Borrowings₹15 Cr
  • Other liabilities₹7 Cr

Profit and loss

Standalone, ₹ crore, years to March.Onyx Biotec half-yearly results

₹ croreMar 2025Filed 28 MayMar 2026Filed 14 May
Revenue from operations62.069.5
51.666.1
Materials and goods bought39.151.7
Employee costs8.68.6
Other expenses3.85.8
Operating profit before depreciation10.33.4
Operating margin16.7%4.9%
Materials, % of revenue63.2%74.4%
Employee costs, % of revenue14.0%12.4%
Other expenses, % of revenue6.2%8.4%
Depreciation and amortisation3.03.1
Operating profit after depreciation7.30.3
Other income1.20.4
Finance costs2.01.2
Profit before tax6.5−0.4
1.5−0.2
Net profit5.0−0.2
Net margin8.0%−0.3%

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2025Filed 28 MayMar 2026Filed 14 May
55.655.4
Share capital18.118.1
Reserves37.537.3
12.515.2
25.732.5
9.97.2
Total assets91.295.2
42.143.9
49.251.3
Net debt3.811.1
Borrowings are counted again inside the liabilities due within a year and after a year.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2025Filed 28 MayMar 2026Filed 14 May
1.4−1.5
−0.4−1.0
−9.7−3.6
Receivables−4.9−7.3
Inventories−7.02.1
Payables2.90.9
Other working capital−0.80.7
Interest paid2.0−0.4
Capital spending1.15.0
Free cash flow0.4−6.5
0.7−4.6
5.11.5
Dividends paid0.00.0
Shares issued25.40.0
Net change in cash7.1−4.6
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2025Filed 28 MayMar 2026Filed 14 May
Earnings per share₹3.30−₹0.12
Diluted earnings per share₹3.30−₹0.12
Book value per share₹30.68₹30.56
Shareholder yield−24.1%0.0%
Market cap at the year end (₹ crore)10562

Ratios

Standalone, years to March.Onyx Biotec PE ratio and valuation

RatioMar 2025Filed 28 MayMar 2026Filed 14 May
Revenue growth–12.1%
Operating profit growth–−67.2%
8.9%−0.4%
–−9.3 pts
From the net margin–−9.3 pts
From asset turnover–0.0 pts
From borrowing–0.0 pts
Return on capital employed10.7%0.5%
Cash conversion28.6%–
Interest cover3.70.3
Debt to equity0.220.27
Receivable days119144
Inventory days15099
Payable days156125
Cash conversion cycle, days113119
Working capital days121132
Asset turnover0.680.75
Assets per rupee of net worth1.641.68
Sales per rupee of plant1.511.77
Capital spending to depreciation0.351.63

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
−0.2%
Cash from operations against operating profit
−44.0%
Measure3 years
Return on equity, average4.3%
Return on capital employed, average5.6%
Operating margin, average10.8%
Net margin, average3.8%
Asset turnover, average0.71
Cash conversion cycle, days, average116
Interest cover, average2.0
Debt to equity, average0.25

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations−1.49
Cash from investing−4.58
Cash from financing1.50
Capital spending4.99
Dividends paid0.00
Shares issued for cash0.00
Borrowings raised2.71
Borrowings repaid0.00

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2025Mar 2026
Receivables growth less revenue growthOur threshold 0 percentage points–23.78
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–−44.80
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–2.10
Effective tax ratePublished threshold 17.16 per cent23.52–
Tax charged less tax paid, % of profitOur threshold 10 percentage points23.52–
A threshold marked as ours has no published figure; it is the line we read the check against.